Inventor · disambiguated record
Bin Jiang
Also filed as: JIANG BIN
30 granted patents·7 pending applications·74 citations·filing 1999–2025
94Inventor score
Files withBRISTOL MYERS SQUIBB CO19DUAN JINGWU3KANG-MIELER JENNIFER J3UNIV NORTHWESTERN3WROBLESKI STEPHEN T3
Top patents by PatentIndex Score
37 records- 0191US10335392B2Cyclic compounds useful as modulators of TNF αBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 2, 2019·5 cites·10 claims
- 0288US8846673B2Azaindazoles as kinase inhibitors and use thereofDUAN JINGWU·Filed 2010·Granted Sep 30, 2014·20 cites·16 claims
- 0386US11266608B2Biodegradable extended release microsphere-hydrogel ocular drug delivery system and methodKANG MIELER JENNIFER J·Filed 2020·Granted Mar 8, 2022·4 cites·20 claims
- 0485US7595317B2Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinasesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Sep 29, 2009·7 cites·14 claims
- 0582US9458171B2Pyrrolidinyl sulfone RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 4, 2016·4 cites·14 claims
- 0682US7888381B2Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereofBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 15, 2011·6 cites·6 claims
- 0780US8034940B2Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Oct 11, 2011·4 cites·11 claims
- 0877US7294624B2Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinasesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Nov 13, 2007·9 cites·14 claims
- 0975US10980882B2Biodegradable microsphere-hydrogel ocular drug delivery systemKANG MIELER JENNIFER J·Filed 2016·Granted Apr 20, 2021·2 cites·20 claims
- 1070US8987268B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Mar 24, 2015·2 cites·14 claims
- 1168US10865191B2Heterocyclic compounds useful as modulators of TNF alphaBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 15, 2020·1 cites·4 claims
- 1268US10463769B2Thromboresistant-anticoagulant extracellular matrixUNIV NORTHWESTERN·Filed 2015·Granted Nov 5, 2019·1 cites·20 claims
- 1367US12312357B2PRMT5 inhibiting compounds and uses thereofANTENGENE DISCOVERY LTD·Filed 2024·Granted May 27, 2025·0 cites·3 claims
- 1467US8324401B2Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofDUAN JINGWU·Filed 2009·Granted Dec 4, 2012·0 cites·10 claims
- 1564US9221826B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Dec 29, 2015·1 cites·10 claims
- 1664US2024115620A1Preparation and therapeutic use of 3d-cultured fibroblastsFibroBiologics·Filed 2023·Application pending·0 cites
- 1763US9771320B2Carbocyclic sulfone RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 26, 2017·1 cites·15 claims
- 1861US7592461B2Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Sep 22, 2009·0 cites·6 claims
- 1961US2011151094A1Method of reducing the enzymatic digestion rates of starch granules in food and food products produced therefromNESTEC SA·Filed 2008·Application pending·0 cites
- 2058US6353112B1Sultams: Solid phase and other synthesis of anti-HIV compounds and compositionsUNIV TENNESSEE RES CORP·Filed 1999·Granted Mar 5, 2002·7 cites·27 claims
- 2156US11078186B2ROR γ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Aug 3, 2021·0 cites·4 claims
- 2250US8304539B2Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofDUAN JINGWU·Filed 2009·Granted Nov 6, 2012·0 cites·19 claims
- 2349US2025206749A1Prmt5 inhibiting compounds and uses thereofANTENGENE DISCOVERY LTD·Filed 2025·Application pending·0 cites
- 2446US9663469B2RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted May 30, 2017·0 cites·6 claims
- 2545US12036234B2Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissuesUNIV NORTHWESTERN·Filed 2018·Granted Jul 16, 2024·0 cites·16 claims
- 2645US9725443B2RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 8, 2017·0 cites·2 claims
- 2745US7625921B2Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Dec 1, 2009·0 cites·14 claims
- 2845US7569689B2Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereofBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 4, 2009·0 cites·15 claims
- 2945US7132432B2Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)BRISTOL MYERS SQUIBB CO·Filed 2004·Granted Nov 7, 2006·0 cites·15 claims
- 3041US2014065226A1Thermo-responsive hydrogel compositionsBREY ERIC·Filed 2012·Application pending·0 cites
- 3141US2016326108A1Pyrrolidinyl sulfone derivatives and their use as ror gamma modulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 3238US8921368B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Dec 30, 2014·0 cites·9 claims
- 3338US2012231072A1Thermo-responsive hydrogel compositionsKANG-MIELER JENNIFER J·Filed 2011·Application pending·0 cites
- 3438US2018201899A1Ipsc-ec performance enhancement via sirt1 overexpressionUNIV NORTHWESTERN·Filed 2016·Application pending·0 cites
- 3534US10189840B2Substituted tricyclic heterocyclic compoundsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 29, 2019·0 cites·9 claims
- 3634US9637455B2Heterocyclic sulfone RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 2, 2017·0 cites·3 claims
- 3732US9708253B2Cyclohexyl sulfone RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jul 18, 2017·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Bin Jiang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →